文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

撒哈拉以南非洲未感染母亲所生儿童乙型肝炎病毒早期水平传播风险:系统综述与荟萃分析

Risk of early horizontal transmission of hepatitis B virus in children of uninfected mothers in sub-Saharan Africa: a systematic review and meta-analysis.
PubMed 文献 · Lancet Glob Health · 2023-01-01

该系统综述与荟萃分析纳入27项研究、10003名HBsAg阴性母亲所生儿童,评估不同疫苗接种程序下早期水平传播风险。未接种组感染风险6.16%,6-8周首剂组0.21%,出生时首剂组0.05%;调整研究时期、地区及母亲HIV状态后,6-8周首剂与出生时首剂组差异无统计学意义(调节效应检验P=0.37)。

要点

  • HBsAg阴性母亲所生儿童即使6-8周开始接种,感染风险也可能极低。
  • 与6-8周首剂相比,出生时首剂未见明确额外获益。
  • 居家分娩且及时接种出生剂困难时,产前HBsAg筛查和选择性出生剂或可优化资源分配。

核心结论

  • HBsAg阴性母亲所生儿童中,即使6-8周开始接种疫苗,感染风险也可能极低,出生剂未见明确额外获益。
  • 当居家分娩且及时接种出生剂困难时,产前HBsAg筛查和选择性出生剂相比普遍出生剂或可更有效分配资源给高风险母婴对。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Global Health、Embase、African Index Medicus和African Journals Online从建库至2022年10月24日。
  • 纳入报告HBsAg阴性母亲所生0-5岁儿童HBsAg或HBV DNA(或两者)的研究,排除仅出生时检测儿童的研究。
  • 共纳入27项研究,评估10003名HBsAg阴性母亲所生儿童。
  • 采用随机效应荟萃分析(广义线性混合模型)合并0-5岁儿童HBsAg或HBV DNA阳性风险。
  • 研究注册于PROSPERO,CRD42021236203。

主要发现

  • 未接种组感染合并风险为6.16%(95%CI 3.05-12.04;155/1407)。
  • 6-8周首剂组感染合并风险为0.21%(95%CI 0.04-1.15;10/3425)。
  • 出生时首剂组感染合并风险为0.05%(95%CI 0.00-1.32;3/2902)。
  • 调整研究时期、地区及母亲HIV状态后,6-8周首剂组与出生时首剂组差异无统计学意义(调节效应检验P=0.37)。

临床怎么用

  • 作者认为,HBsAg阴性母亲所生儿童即使6-8周开始接种,感染风险也可能极低,出生剂未见明确额外获益。
  • 作者认为,当居家分娩且及时接种出生剂困难时,产前HBsAg筛查和选择性出生剂相比普遍出生剂或可更有效分配资源给高风险母婴对。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sub-Saharan Africa is highly endemic for hepatitis B virus (HBV); historically, most people were exposed during childhood through vertical or horizontal transmission. Although all African countries now provide a three-dose infant hepatitis B vaccination starting at age 6-8 weeks, only a third of African countries have introduced birth dose (HepB-BD) vaccine. Adding HepB-BD is fundamental to prevent vertical transmission, but its effectiveness in preventing horizontal transmission, compared with the three-dose infant vaccination alone, is unknown. We aimed to estimate the risk of early horizontal transmission in children of hepatitis B surface antigen (HBsAg)-negative mothers in sub-Saharan Africa stratified according to the vaccination schedule. METHODS: In this systematic review and meta-analysis we searched MEDLINE, Global Health, Embase, African Index Medicus and African Journals Online from their inception to Oct 24, 2022, for studies reporting HBsAg or HBV DNA, or both, in children (aged 0-5 years) of HBsAg-negative mothers. We excluded studies if children were only tested at birth. Two reviewers independently screened the titles and abstracts of all articles and data were extracted using a standardised pre-piloted data extraction sheet, and authors were contacted if any important information was missing. The primary outcome was the risk of HBV infection in children of HBsAg-negative mothers, stratified by vaccination schedule (no vaccination, first dose at 6-8 weeks, or first dose at birth). We pooled the child risks of HBsAg or HBV DNA-positivity from the age of 0 years to 5 years via a random-effect meta-analysis using a generalised linear mixed model. The study was registered on PROSPERO, CRD42021236203. FINDINGS: Of 8856 articles identified, 27 studies evaluating 10 003 children of HBsAg-negative mothers were included. The pooled risks of infection were 6·16% (95% CI 3·05-12·04; 155/1407) in the no vaccination group, 0·21% (0·04-1·15; 10/3425) in children who received their first dose at 6-8 weeks, and 0·05% (0·00-1·32; 3/2902) in children who received their first dose at birth. The difference was not statistically significant in children who received their first dose at 6-8 weeks and children who received their first dose at birth after adjusting for the study period, region, and maternal HIV status (test of moderators p=0·37). INTERPRETATION: In children of HBsAg-negative mothers, the risk of infection might be minimal even with the vaccination starting at 6-8 weeks, without clear additional benefit from HepB-BD. When births take place at home and timely administration of HepB-BD is challenging, antenatal HBsAg screening and selective HepB-BD might allow efficient allocation of resources to mother and child pairs at high risk compared with universal HepB-BD. FUNDING: None. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Ansari A, Vincent JP, Moorhouse L, et al. Risk of early horizontal transmission of hepatitis B virus in children of uninfected mothers in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2023. PMID: 37061310. doi:10.1016/S2214-109X(23)00131-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。